The TSX Venture Exchange has accepted for filing Royal Sapphire Corp.'s change of business (COB) and related transactions, all as principally described in its filing statement dated July 5, 2018. The COB includes the following matters, all of which have been accepted by the exchange.

Acquisition of all of the shares of PureSinse Inc.

On May 17, 2018, Royal Sapphire entered into an amalgamation agreement with PureSinse and 2627000 Ontario Inc. (Subco), a wholly owned subsidiary of Royal Sapphire. Pursuant to the amalgamation agreement, Subco and PureSinse amalgamated to form an amalgamated company which is a wholly owned subsidiary of Royal Sapphire, and Royal Sapphire acquired all of the issued and outstanding PureSinse shares in exchange for the issuance of an aggregate of 75,574,447 resulting issuer shares to the existing PureSinse shareholders on a basis of one resulting issuer share for every PureSinse share.

PureSinse is a life sciences cannabis company based in Toronto. The company is a licensed producer under the Access to Cannabis for Medical Purposes Regulations and is focused on producing cannabis products for medical, wellness and future legal adult recreational use, from its 18,000-square-foot facility, located in Brampton, Ont.

For additional information, please refer to the filing statement dated July 5, 2018, available under Royal Sapphire's profile on SEDAR.

The TSX Venture Exchange has accepted for filing documentation with respect to a non-brokered private placement announced March 16, 2018.

Number of shares:  27.9 million postconsolidated shares

Purchase price:  33 cents per share

Number of placees:  124 placees